← All trials
NCT07297290
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 23, 2025
- Primary completion
- Mar 31, 2027
- Completion date
- Sep 30, 2027
- First posted
- Dec 22, 2025
- Last posted
- Dec 22, 2025
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NigeriaLead sponsor
- Cures Within ReachCollaborator
- University of NigeriaOfficial
- University of NigeriaSponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.